These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23528223)

  • 21. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
    González de Requena D; Gallego O; Valer L; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):275-8. PubMed ID: 15117450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
    Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
    Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.
    Zhu D; Taguchi-Nakamura H; Goto M; Odawara T; Nakamura T; Yamada H; Kotaki H; Sugiura W; Iwamoto A; Kitamura Y
    Antivir Ther; 2004 Dec; 9(6):929-35. PubMed ID: 15651752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR
    Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
    HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.
    Machado DM; Gouvêa Ade F; Cardoso MR; Beltrão SV; Cunegundes KS; Bononi F; Almeida F; Cavalheiro K; Angelis DS; Succi RC
    Braz J Infect Dis; 2007 Feb; 11(1):16-9. PubMed ID: 17625720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma metabolic changes in Chinese HIV-infected patients receiving lopinavir/ritonavir based treatment: Implications for HIV precision therapy.
    Li X; Wu T; Jiang Y; Zhang Z; Han X; Geng W; Ding H; Kang J; Wang Q; Shang H
    Cytokine; 2018 Oct; 110():204-212. PubMed ID: 29778008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
    Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
    J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients.
    Bouazza N; Urien S; Blanche S; Hirt D; Foissac F; Benaboud S; Tréluyer JM; Frange P
    Pediatr Infect Dis J; 2014 Aug; 33(8):e213-8. PubMed ID: 24509655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
    Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
    Luis Jiménez J; Resino S; Martinez-Colom A; Bellón JM; Angeles Muñoz-Fernández M;
    J Antimicrob Chemother; 2005 Dec; 56(6):1081-6. PubMed ID: 16195257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.